The news: Pathology provider Healius has appointed UBS to explore a sale of its bioanalytical laboratory Agilex Biolabs in response to \u201cseveral unsolicited approaches from credible parties\u201d.<\/p>\n
The context: Agilex Biolabs current operates as a standalone business within Healius and any sale would not impact the company\u2019s core pathology operations, it said.<\/p>\n
The group also said it expects to deliver group underlying EBITDA of between $259 million and $264 million for FY26, and underlying EBIT of between $30 million and $35 million.<\/p>\n
It had previously guided for full-year earnings \u201cto be in line with current consensus\u201d.<\/p>\n
Healius reported underlying EBITDA of $239.3 million in FY25, and underlying EBIT of $17.1 million.<\/p>\n
The company said on Wednesday that pathology volumes declined 0.4% for the 10 months to April 2026, while revenue had grown by 2.4%.<\/p>\n
Pathology labour costs increased by 0.8% during the same period, where previous guidance was broadly flat for FY26.<\/p>\n
Healius noted that pathology labour costs will be impacted by $1.8 million in the fourth quarter, due to the Fair Work Commission\u2019s interim findings on gender-based undervaluation.<\/p>\n
Elsewhere, Healius flagged that last night\u2019s federal budget contained no new funding for pathology, noting the sector is already operating under an indexation freeze for most tests.<\/p>\n
What they said: \u201cPressure on the pathology sector continues to build as we navigate a significant wage increase as the result of the Fair Work Commission decision on gender-based valuation,\u201d the company said.<\/p>\n
\u201cDespite the fact that GPs and patients rely on pathology tests, the pathology sector is receiving no support to fund these increases.<\/p>\n
\u201cInadequate funding has resulted in difficult decisions to cut staff, close collection centres and regional laboratories. This year\u2019s federal budget will put additional pressure on a sector which is a critical part of Australia\u2019s primary healthcare system.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"The news: Pathology provider Healius has appointed UBS to explore a sale of its bioanalytical laboratory Agilex Biolabs…\n","protected":false},"author":2,"featured_media":64400,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129],"tags":[35160,4128,231,223],"class_list":{"0":"post-64399","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ubs","8":"tag-asxhls","9":"tag-healthcare","10":"tag-markets","11":"tag-ubs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116564294530117281","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=64399"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/64399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/64400"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=64399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=64399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=64399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}